Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old

Each year, around 300,000 Herpes Zoster (HZ) cases are observed in the German population, resulting in costs over €182 million to society. The objective of this study was to estimate the potential public health and economic impact of the new Adjuvanted Recombinant Zoster Vaccine (RZV, Shingrix) in t...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Hum Vaccin Immunother
Main Authors: Van Oorschot, Desirée, Anastassopoulou, Anastassia, Poulsen Nautrup, Barbara, Varghese, Lijoy, von Krempelhuber, Alfred, Neine, Mohamed, Lorenc, Stéphane, Curran, Desmond
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2018
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6363061/
https://ncbi.nlm.nih.gov/pubmed/30130448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1509645
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares